Risk for death reduced with higher versus lower levels of anti-SARS-CoV-2 IgG, but only in patients not receiving mechanical ventilation
TUESDAY, Jan. 19, 2021 (HealthDay News) — For patients hospitalized with COVID-19 and not receiving mechanical ventilation, the risk for death is reduced with transfusion of plasma with higher versus lower levels of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies, according to a study published online Jan. 13 in the New England Journal of Medicine.
Michael J. Joyner, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues determined the anti-SARS-CoV-2 IgG levels in convalescent plasma used to treat hospitalized adults with COVID-19. A total of 3,082 patients were included in the analysis: 515 in the high-titer group, 2,006 in the medium-titer group, and 561 in the low-titer group.
The researchers found that death within 30 days after plasma transfusion occurred in 22.3, 27.4, and 29.6 percent of patients in the high-, medium-, and low-titer groups, respectively. The association between anti-SARS-CoV-2 antibody levels and risk for death from COVID-19 was moderated by mechanical ventilation status. For patients who had not received mechanical ventilation before transfusion, the risk for death within 30 days was lower in the high- versus low-titer group (relative risk, 0.66; 95 percent confidence interval, 0.48 to 0.91), while no effect on risk for death was seen for patients who had received mechanical ventilation (relative risk, 1.02; 95 percent confidence interval, 0.78 to 1.32).
“These data show that the benefit of convalescent plasma was most apparent in patients who received plasma transfusions containing higher levels of anti-SARS-CoV-2 IgG antibodies early in the disease course,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Millennium Pharmaceuticals and Octapharma USA, which provided donations for the study.
Copyright © 2020 HealthDay. All rights reserved.
